文献速递肿瘤 PET/CT

预测口咽癌放疗后生存的18F-FDG-PET影像组学模型的外部验证

External validation of an 18F-FDG-PET radiomic model predicting survival after radiotherapy for oropharyngeal cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-01-05

本研究对已发表的18F-FDG-PET影像组学模型进行外部验证,纳入100例接受放化疗的口咽癌患者。在66例有HPV信息的亚组中,全局风险评分R与癌症特异性生存相关(p=0.05,C-index=0.75),但单独使用代谢肿瘤体积(MTV)的预测性能与模型相似,未提高预测准确性。

要点

  • 在66例有HPV信息的亚组中,全局风险评分R与癌症特异性生存相关(p=0.05),C-index为0.75(95%CI 0.62-0.85)。
  • 最佳截断值0.15能有效分层患者(p=0.01,HR=7.4,95%CI 1.6-11.4),低危组5年癌症特异性生存为97%(95%CI 93-100%),高危组为74%(56-92%)。
  • 单独使用影像组学风险评分RF或MTV的预测性能与全局模型几乎相同,模型未提高预测准确性。

核心结论

  • 一个先前发表的PET影像组学模型被独立验证用于预测癌症特异性生存,但其性能与单独使用MTV相似,未提高预测准确性。

研究设计与样本

  • 外部验证研究,纳入100例接受同步化疗(66-69 Gy/30次)的口咽癌患者(IV期78例),放疗前PET图像按IBSI指南提取450个影像组学特征。
  • 仅一个癌症特异性生存预测模型符合独立测试标准,该模型包含HPV状态、SUVmean、SUVmax和两个独立元因子。
  • 在66例有完整HPV信息的亚组中,计算全局风险评分R并采用Cox回归测试其对癌症特异性生存的预测价值。
  • 在同一亚组中独立测试仅由元因子衍生的影像组学风险评分RF,并将MTV作为单一预测因子进行比较。
  • MTV和RF的验证也在整个数据集中进行。

主要发现

  • 在66例有HPV信息的亚组中,中位随访41.6个月,7例患者死于癌症。
  • 全局风险评分R与癌症特异性生存相关(p=0.05),C-index为0.75(95%CI 0.62-0.85)。
  • 最佳截断值0.15能有效分层患者(p=0.01,HR=7.4,95%CI 1.6-11.4),低危组5年癌症特异性生存为97%(95%CI 93-100%),高危组为74%(95%CI 56-92%)。
  • 单独使用RF或MTV也与癌症特异性生存显著相关,C-index几乎相同;按最佳截断值(RF>0.12和MTV>15.5cc),RF低危组5年癌症特异性生存为96%(95%CI 89-100%),高危组为65%(95%CI 36-94%);MTV低危组为97%(95%CI 88-100%),高危组为77%(95%CI 58-93%)。
  • RF和MTV的结果在整个数据集中得到确认。

关键数值与推荐

  • 全局风险评分R最佳截断值为0.15,低危组5年癌症特异性生存为97%(95%CI 93-100%),高危组为74%(95%CI 56-92%)。
  • 影像组学风险评分RF最佳截断值为>0.12,低危组5年癌症特异性生存为96%(95%CI 89-100%),高危组为65%(95%CI 36-94%)。
  • MTV最佳截断值为>15.5cc,低危组5年癌症特异性生存为97%(95%CI 88-100%),高危组为77%(95%CI 58-93%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE: The purpose of the study is to externally validate published 18F-FDG-PET radiomic models for outcome prediction in patients with oropharyngeal cancer treated with chemoradiotherapy. MATERIAL/METHODS: Outcome data and pre-radiotherapy PET images of 100 oropharyngeal cancer patients (stage IV:78) treated with concomitant chemotherapy to 66-69 Gy/30 fr were available. Tumors were segmented using a previously validated semi-automatic method; 450 radiomic features (RF) were extracted according to IBSI (Image Biomarker Standardization Initiative) guidelines. Only one model for cancer-specific survival (CSS) prediction was suitable to be independently tested, according to our criteria. This model, in addition to HPV status, SUVmean and SUVmax, included two independent meta-factors (Fi), resulting from combining selected RF clusters. In a subgroup of 66 patients with complete HPV information, the global risk score R was computed considering the original coefficients and was tested by Cox regression as predictive of CSS. Independently, only the radiomic risk score RF derived from Fi was tested on the same subgroup to learn about the radiomics contribution to the model. The metabolic tumor volume (MTV) was also tested as a single predictor and its prediction performances were compared to the global and radiomic models. Finally, the validation of MTV and the radiomic score RF were also tested on the entire dataset. RESULTS: Regarding the analysis of the subgroup with HPV information, with a median follow-up of 41.6 months, seven patients died due to cancer. R was confirmed to be associated to CSS (p value = 0.05) with a C-index equal 0.75 (95% CI=0.62-0.85). The best cut-off value (equal to 0.15) showed high ability in patient stratification (p=0.01, HR=7.4, 95% CI=1.6-11.4). The 5-year CSS for R were 97% (95% CI: 93-100%) vs 74% (56-92%) for low- and high-risk groups, respectively. RF and MTV alone were also significantly associated to CSS for the subgroup with an almost identical C-index. According to best cut-off value (RF>0.12 and MTV>15.5cc), the 5-year CSS were 96% (95% CI: 89-100%) vs 65% (36-94%) and 97% (95% CI: 88-100%) vs 77% (58-93%) for RF and MTV, respectively. Results regarding RF and MTV were confirmed in the overall group. CONCLUSION: A previously published PET radiomic model for CSS prediction was independently validated. Performances of the model were similar to the ones of using only the MTV, without improvement of prediction accuracy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mori M, Deantoni C, Olivieri M, et al. External validation of an 18F-FDG-PET radiomic model predicting survival after radiotherapy for oropharyngeal cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 36604325. doi:10.1007/s00259-022-06098-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。